Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes

NCT03113994 is registered in ClinicalTrials.gov with Dr. B. Catharine. Craven as lead sponsor.

NCT NCT03113994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03113994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes
Lead sponsor
Dr. B. Catharine. Craven
Phase
Phase 2
Overall status
Terminated
Start date
February 26, 2018
Completion date
December 31, 2022
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic syndrome, osteoporosis, spinal cord injuries